New Sarms Powder ACP-105 benefit dosage for bodybuilder loss fat

Product link to :https://www.astersteroids.com/new-sarms-powder-acp-105-benefit-dosage-for-bodybuilder-loss-fat-cas899821-23-9/
Product Name: ACP-105
Synonyms: ACP105; ACP 105; ACE-XT;
CAS: 899821-23-9
MF:C16H19ClN2O
MW:290.79
Appearance:White powder
Purity: 99.% min
Package: 10g/bag or as customers'request.
Test Method: HPLC

Benefit:
▪ Increased growth of lean muscle mass and tissues
▪ Excellent for individuals with muscle-wasting conditions and osteoporosis
▪ Gain more muscles quickly and easily
▪ Increased strength
▪ Bone strength and density
▪ Increased on balance
▪ Speed
▪ Endurance
▪ Motor coordination
▪ Fat loss
Application: ACP-105 is part of a class of molecules referred to as selective androgen receptor modulators (SARMs). SARMs may advance the standard of treatment for a variety of disorders including muscle-wasting conditions and osteoporosis, with fewer side effects as compared to current treatments based on test replacement. ACP-105 has exhibited promising pharmacological properties and a favorable safety profile in preclinical testing.

How Strong Is ACP-105?
To get a clear representation of just how strong of an effect this SARM has, each research subject undergoes ORX-induced atrophy (an orchiectomy), which is a surgical procedure in which one or both testicles are removed.
This is the surgical form of castration.
The point of this is that once the ACP-105 is administered to the research subjects, you can calculate an exact figure that defines how anabolic and androgenic a compound is, based on the fact that there are no longer endogenous hormones skewing the results, and the research subject is essentially functioning from a baseline reading of 0 on all accounts.
1mg/kg per day was given to the research subjects, and that resulted in a very blatant anabolic effect.
The extent of this anabolic effect is measured in what % of hypertrophy occurs relative to the baseline that DHT would otherwise achieve had the research subject not undergone ORX-induced atrophy.
The % of anabolic activity was determined to be 67%, with only 21% reversal of the prostate gland (which is used to measure androgenic activity).
From this we can conclude that this SARM has an anabolic:androgenic rating/ratio of 3.19:1
There are several SARMs that have anabolic:androgenic ratios of 3:1 and up though, so this is fairly typical.
While we can vaguely gather what we can expect from this compound (the comparisons that come to mind are Ostarine and S4), without knowing the binding affinity of the compound we can essentially only make shot in the dark guesses.
We do know what kind of interaction ACP-105 has with the androgen receptor though, which helps shed light on things a bit more.
Based on the information that was available, we know that ACP-105 is a partial agonist.
Full agonists induce greater levels of suppression, but are more potent (based on the information presented).
Partial agonists on the other hand, are less suppressive, but are typically weaker relative to Testosterone and DHT, which is the case with ACP-105.
A fairly low concentration of ACP-105 attaches to the androgen receptor better than DHT does, and is blatantly weaker than Testosterone and DHT in general.
In one sense, this is a disappointment as we are all awaiting the release of the end all be all SARM that is only exerts minor suppression, has minimal/zero androgenic side effects, and can rival or beat Testosterone in overall anabolic activity.
This is asking a lot though, and it would be more useful to simply compare ACP-105 to the other most promising mainstream SARMs to determine if it has a place in a researchers up and coming test protocols.